Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) has received approval from the National Medical Products Administration for its self-developed B023 cell injection, a Class I innovative biological product aimed at treating inoperable locally advanced or metastatic solid tumors that have failed standard treatments [1] Group 1: Product Development - The B023 cell injection is developed by Shanghai Pharmaceuticals' subsidiary, Shanghai Pharmaceuticals Group Biotherapy Technology Co., Ltd [1] - The core component of B023 is invariant natural killer T (iNKT) cells, which are a type of non-classical T cell with a constant T cell receptor (TCR) [1] - iNKT cells can be used in allogeneic applications without causing graft-versus-host disease (GvHD) due to the lack of polymorphism in the CD1d molecule in the human population [1] Group 2: Financial Investment - As of the date of the announcement, the total research and development investment for the B023 project has reached approximately 39.2584 million RMB [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for its self-developed B023 cell injection, marking a significant advancement in innovative biopharmaceuticals targeting late-stage or metastatic solid tumors that are not amenable to surgery [1] Group 1: Product Development - B023 cell injection is classified as a Class I innovative biopharmaceutical, specifically designed for patients with locally advanced or metastatic solid tumors that have failed standard treatments and lack effective therapeutic options [1] - The core component of B023 is invariant natural killer T (iNKT) cells, which are a type of non-classical T cell with a constant T cell receptor (TCR) that can be applied universally without causing graft-versus-host disease (GvHD) [1] - The project has been entirely developed by Shanghai Pharmaceuticals' subsidiary, Shanghai Pharmaceuticals Group Biotherapy Technology Co., Ltd., and the company holds complete intellectual property rights for the product [1] Group 2: Financial Investment - As of the date of the announcement, the total research and development investment for the B023 project has reached approximately 39.2584 million RMB [1] - There are currently no other products with the same indication and type available in the global market, highlighting the uniqueness of B023 [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Pharmaceuticals Group Biotherapy Technology Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of its self-developed B023 cell injection [1] Group 1: Product Development - B023 cell injection is an innovative Class I biopharmaceutical developed and produced by Shanghai Pharmaceuticals Biotherapy, targeting locally advanced or metastatic solid tumors that are inoperable and have no effective treatment options after standard therapy failure [1] - The core component of B023 is invariant natural killer T (iNKT) cells, which are a type of non-classical T cell with a constant T cell receptor (TCR) [1] - Human iNKT cells have TCR chains TCRvα24 and TCRvβ11, which recognize lipid antigens presented by MHC class I molecule CD1d [1] Group 2: Clinical Implications - CD1d is non-polymorphic in the population, allowing for the allogeneic application of iNKT cells without causing graft-versus-host disease (GvHD), making it a universal cell type [1]

Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Pharmaceuticals Biologicals, has received the Clinical Trial Approval Notice from the National Medical Products Administration for its self-developed "B023 Cell Injection" [1] Group 1: Product Development - B023 Cell Injection is an innovative Class I biological product developed and produced by Shanghai Pharmaceuticals Biologicals, with the core component being invariant natural killer T cells (iNKT) [1] - The clinical intended use for B023 is for locally advanced or metastatic solid tumors that are inoperable and have failed standard treatments, with no effective treatment options available [1] - As of the announcement date, the project has accumulated research and development expenses of approximately 39.2584 million RMB [1] Group 2: Market Position - There are currently no other drugs on the global market with the same variety and indication as B023 Cell Injection [1]